ADVERTISEMENT
U.S. President Donald Trump said that tariffs on imported pharmaceuticals can be as much as 250 percent after initially levying a “small tariff” and then spiking it to 150 percent to give a fillip to domestic production of pharmaceuticals.
Trump, who was speaking to CNBC in an interview, did not specify what the initial tariffs on pharmaceuticals would be. The U.S. has been undertaking a national security review of the pharmaceutical sector. It is not known when the results of the review will be announced, but the industry has been taking contingency measures, preempting sector-specific tariffs. More recently, AstraZeneca said that it has earmarked an investment of $50 billion to expand manufacturing and research facilities in the U.S. by 2030.
According to data compiled by Nomura, pharmaceuticals make up about 37% of India’s sectoral exports, with 12% of the exports going to the U.S. While pharmaceuticals and electronics are exempted from reciprocal tariffs under the U.S. Section 232 trade investigations, any sectoral tariffs levied on pharmaceuticals will be passed on to end-consumers, which, in turn, would affect the export volumes.
August 2025
As India continues to be the world’s fastest-growing major economy, Fortune India presents its special issue on the nation’s Top 100 Billionaires. Curated in partnership with Waterfield Advisors, this year’s list reflects a slight decline in the number of dollar billionaires—from 185 to 182—even as the entry threshold for the Top 100 rose to ₹24,283 crore, up from ₹22,739 crore last year. From stalwarts like Mukesh Ambani, Gautam Adani, and the Mistry family, who continue to lead the list, to major gainers such as Sunil Mittal and Kumar Mangalam Birla, the issue goes beyond the numbers to explore the resilience, ambition, and strategic foresight that define India’s wealth creators. Read their compelling stories in the latest issue of Fortune India. On stands now.
Sanjaya Mariwala, the executive chairman and managing director of OmniActive Health Technologies, said that pharmaceuticals and electronics would take the biggest hit with the imposition of tariffs and a fine for importing oil from Russia.
Beyond the monetary implications, the tariffs would interrupt smooth trade flow, inflate U.S. drug costs, stall treatments, and could even put greater pressure on American healthcare budgets. “Back home, the profits for Indian pharmaceutical companies may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances,” he said.
Trump also told CNBC that it will impose substantially higher tariffs on India in the next 24 hours, a day after he launched a fresh salvo at India over the import of oil from Russia. His comments came close on the heels of the Indian government issuing a strong rejoinder against Trump’s threats, repudiating that the U.S. is unfairly targeting India when imports by the U.S. and the EU were much higher than India’s.
Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.